Targeted Alpha Radiopharmaceutical Therapy and Key Considerations for Nuclear Medicine Technologists

Abstract

The use of radionuclides for targeted radiopharmaceutical therapy (RPT) is a rapidly evolving field in nuclear medicine and oncology. With the integration of imaging and therapy, therapeutic nuclear medicine has made remarkable progress in recent years. One particularly promising area of research is the use of α-emitting radionuclides, which possess unique physical properties that provide notable advantages, including the ability to target single tumor cells with high precision. Although the only targeted α therapy (TAT) currently approved by the United States Food and Drug Administration is ²²³Ra-dichloride for the treatment of castration-resistant prostate cancer with skeletal metastases, a search on clinicaltrials.gov yields a significant number of early- and late-stage clinical trials utilizing 223-Ra, 225-Ac, 211-At, 212-Pb, and 227-Th are in progress, indicating that more TATs are on the horizon. As the prevalence of use for TAT increases, it is important to consider the logistics of TAT administration and the requirements for radiation safety and patient discharge. This review aims to provide a comprehensive overview of the advancements, relevant clinical trials, and logistical considerations associated with targeted α RPT in oncology.

Keywords

alpha-particle - beta-particle - molecular target - radiopharmaceutical therapy - targeted α therapy

Authors' Contributions

J.B. was the primary author of the manuscript. She was also responsible for resource gathering and review, clinical trials review, authorship of four-fifths tables, manuscript review, and manuscript revisions. D.G. was responsible for secondary authorship of the manuscript, manuscript review, and authorship of the radiation safety/discharge instructions table and other clinical recommendations. J.B. and D.G. have read and approved the manuscript. Both authors believe the manuscript represents honest work.

Publication History

Article published online:
03 June 2025

• References

• 1 Bruland ØS, Larsen RH, Baum RP, Juzeniene A. Editorial: targeted alpha particle therapy in oncology. Front Med (Lausanne) 2023; 10: 1165747
• 2 Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. α-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1. J Nucl Med 2018; 59 (06) 878-884
• 3 Clinical Trials.[online]. Accessed September 13, 2024 at: clinicaltrials.gov
• 4 Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol 2021; 92: 228-240
• 5 Pallares RM, Abergel RJ. Development of radiopharmaceuticals for targeted alpha therapy: where do we stand?. Front Med (Lausanne) 2022; 9: 1020188
• 6 Heskamp S, Hernandez R, Molkenboer-Kuenen JDM. et al. α- Versus β-emitting radionuclides for pretargeted radioimmunotherapy of carcinoembryonic antigen-expressing human colon cancer xenografts. J Nucl Med 2017; 58 (06) 926-933
• 7 Serencsits B, Chu BP, Pandit-Taskar N, McDevitt MR, Dauer LT. Radiation safety considerations and clinical advantages of α-emitting therapy radionuclides. J Nucl Med Technol 2022; 50 (01) 10-16